Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 18093
Country/Region: Democratic Republic of the Congo
Year: 2017
Main Partner: Elizabeth Glaser Pediatric AIDS Foundation
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $4,326,816 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $653,420
Care: TB/HIV (HVTB) $76,673
Care: Pediatric Care and Support (PDCS) $168,448
Laboratory Infrastructure (HLAB) $71,000
Strategic Information (HVSI) $100,000
Health Systems Strengthening (OHSS) $180,000
Biomedical Prevention: Injection Safety (HMIN) $10,000
Testing: HIV Testing and Counseling (HVCT) $1,068,682
Sexual Prevention: Other Sexual Prevention (HVOP) $74,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $414,164
Treatment: Adult Treatment (HTXS) $1,304,073
Treatment: Pediatric Treatment (PDTX) $206,356
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 3
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 12
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 6
GEND_GBV Number of people receiving post-GBV care 2018 18
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 188,845
HTS_TST Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative 2018 182
HTS_TST Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative 2018 152
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative 2018 449
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative 2018 679
HTS_TST Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative 2018 539
HTS_TST Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative 2018 539
HTS_TST Service Delivery Point by Agg Age (Facility) ANC: <15, Negative 2018 1,862
HTS_TST Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative 2018 35,355
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative 2018 770
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative 2018 678
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative 2018 11,972
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative 2018 7,789
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative 2018 6,379
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative 2018 5,562
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 52,652
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 35,115
HTS_TST Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative 2018 135
HTS_TST Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative 2018 94
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative 2018 4,832
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative 2018 3,092
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative 2018 9
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative 2018 1
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative 2018 6,578
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative 2018 4,711
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative 2018 2,140
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative 2018 2,144
HTS_TST Sum of Test Result disaggregates 2018 4,435
HTS_TST_POS By Test Result: Positive 2018 4,435
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive 2018 48
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive 2018 26
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive 2018 112
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive 2018 168
HTS_TST_POS Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive 2018 28
HTS_TST_POS Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive 2018 28
HTS_TST_POS Service Delivery Point by Agg Age (Facility) ANC: <15, Positive 2018 13
HTS_TST_POS Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive 2018 232
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive 2018 14
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive 2018 6
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive 2018 390
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive 2018 249
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive 2018 120
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive 2018 90
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 1,315
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 886
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive 2018 10
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive 2018 235
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive 2018 154
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive 2018 136
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive 2018 91
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive 2018 43
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive 2018 39
PMTCT_ART Already on ART at beginning of current pregnancy 2018 78
PMTCT_ART New on ART 2018 269
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 347
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 37,573
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 339
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 49
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 272
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 3
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 15
PMTCT_STAT By Age (Numerator): 10-14 2018 1,879
PMTCT_STAT By Age (Numerator): 15-19 2018 5,634
PMTCT_STAT By Age (Numerator): 20-24 2018 15,048
PMTCT_STAT By Age (Numerator): 25-49 2018 15,012
PMTCT_STAT By Number of known positives: 10-14 2018 5
PMTCT_STAT By Number of known positives: 15-19 2018 20
PMTCT_STAT By Number of known positives: 20-24 2018 45
PMTCT_STAT By Number of known positives: 25-49 2018 45
PMTCT_STAT By Number of new negative: 10-14 2018 1,863
PMTCT_STAT By Number of new negative: 15-19 2018 5,577
PMTCT_STAT By Number of new negative: 20-24 2018 14,875
PMTCT_STAT By Number of new negative: 25-49 2018 14,900
PMTCT_STAT By Number of new positives: 10-14 2018 12
PMTCT_STAT By Number of new positives: 15-19 2018 37
PMTCT_STAT By Number of new positives: 20-24 2018 97
PMTCT_STAT By Number of new positives: 25-49 2018 97
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 37,573
PMTCT_STAT_den By Age (Denominator): <15-19 2018 5,751
PMTCT_STAT_den By Age (Denominator): 10-14 2018 1,918
PMTCT_STAT_den By Age (Denominator): 20-24 2018 15,334
PMTCT_STAT_den By Age (Denominator): 25-49 2018 15,339
PP_PREV Age/sex: 15-19 Female 2018 75
PP_PREV Age/sex: 15-19 Male 2018 175
PP_PREV Age/sex: 20-24 Female 2018 75
PP_PREV Age/sex: 20-24 Male 2018 175
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 500
PP_PREV Sum of Age/Sex disaggregates 2018 500
PrEP_NEW Female 20-24 2018 5
PrEP_NEW Female 25-49 2018 20
PrEP_NEW Male 20-24 2018 15
PrEP_NEW Male 25-49 2018 30
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2018 70
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 7
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 99
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 10
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 127
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 243
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 243
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 7
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 99
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 10
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 127
TB_PREV By Age/Sex (Numerator): <15, Female 2018 87
TB_PREV By Age/Sex (Numerator): <15, Male 2018 74
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 980
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 664
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 1,805
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 1,805
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 2,123
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 102
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 86
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 1,158
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 777
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 2,123
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 129
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 1,484
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 164
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 1,895
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 3,672
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 3,672
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 129
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 1,484
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 164
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 1,895
TX_CURR Aggregated Age/Sex: <15 Female 2018 361
TX_CURR Aggregated Age/Sex: <15 Male 2018 323
TX_CURR Aggregated Age/Sex: 15+ Female 2018 6,347
TX_CURR Aggregated Age/Sex: 15+ Male 2018 2,273
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 9,304
TX_CURR Sum of Aggregated Age/Sex <15 2018 684
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 8,620
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 9,304
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 169
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 144
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 1,925
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 1,300
TX_NEW Breastfeeding status 2018 99
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 3,538
TX_NEW Pregnancy status 2018 424
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 3,538
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 6,060
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 4,834
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 187
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 1
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 138
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 1
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 3,266
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 59
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 1,162
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 20
TX_PVLS Numerator: Indication: Routine 2018 4,753
TX_PVLS Numerator: Indication: Targeted 2018 81
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 232
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 1
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 188
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 1
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 4,076
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 77
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 1,460
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 24
TX_PVLS_den Denominator: Indication: Routine 2018 5,957
TX_PVLS_den Denominator: Indication: Targeted 2018 103
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 140
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 121
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,616
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,093
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 2,970
TX_RET Numerator by Status: Breastfeeding 2018 90
TX_RET Numerator by Status: Pregnant 2018 594
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 3,537
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 169
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 144
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 1,927
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 1,297
TX_RET_den Denominator by Status: Breastfeeding 2018 21
TX_RET_den Denominator by Status: Pregnant 2018 707
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 9,304
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 92
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 4
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 4
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 61
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 23
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 7
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 7
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 127
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 45
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 20
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 7
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 158
TX_TB_den Denominator: By Screen Result: Negative 2018 9,198
TX_TB_den Denominator: By Screen Result: Positive 2018 186
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 186
Cross Cutting Budget Categories and Known Amounts Total: $160,000
Gender: Gender Based Violence (GBV) $40,000
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Motor Vehicles: Purchased $80,000
Water $40,000